|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) | ||
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Series A Conv Preferred Stock | (1) | 02/25/2009 | C | 616,197 | (4) | (4) | Common Stock | 616,197 | $ 0 | 0 | D | ||||
| Warrant | (3) | 02/25/2009 | C | 87,499 | 07/19/2006 | 07/19/2011 | Series A Conv Preferred Stock | 87,499 | $ 0 | 0 | D | ||||
| Warrant | (3) | 02/25/2009 | C | 87,499 | 07/19/2006 | 07/19/2011 | Common Stock | 87,499 | $ 0 | 87,499 | D | ||||
| Warrant | (5) | 02/25/2009 | U | 87,499 | (5) | (5) | Common Stock | 87,499 | $ 0 | 0 | D | ||||
| Warrant | (5) | 02/25/2009 | U | 234,339 | (5) | (5) | Common Stock | 234,339 | $ 0 | 0 | D | ||||
| Series A Conv Preferred Stock | (1) | 02/25/2009 | C | 616,197 | (4) | (4) | Common Stock | 616,197 | $ 0 | 0 | I | Held by Easton Hunt Capital Partners, L.P. | |||
| Warrant | (3) | 02/25/2009 | C | 87,499 | 07/19/2006 | 07/19/2011 | Series A Conv Preferred Stock | 87,499 | $ 0 | 0 | I | Held by Easton Hunt Capital Partners, L.P. | |||
| Warrant | (3) | 02/25/2009 | C | 87,499 | 07/19/2006 | 07/19/2011 | Common Stock | 87,499 | $ 0 | 87,499 | I | Held by Easton Hunt Capital Partners, L.P. | |||
| Warrant | (5) | 02/25/2009 | U | 87,499 | (5) | (5) | Common Stock | 87,499 | $ 0 | 0 | I | Held by Easton Hunt Capital Partners, L.P. | |||
| Warrant | (5) | 02/25/2009 | U | 166,667 | (5) | (5) | Common Stock | 166,667 | $ 0 | 0 | I | Held by Easton Hunt Capital Partners, L.P. | |||
| Warrant | (5) | 02/25/2009 | U | 234,339 | (5) | (5) | Common Stock | 234,339 | $ 0 | 0 | I | Held by Easton Hunt Capital Partners, L.P. | |||
| Reporting Owner Name / Address | Relationships | |||
| Director | 10% Owner | Officer | Other | |
| EASTON CAPITAL PARTNERS L P 641 LEXINGTON AVE NEW YORK, NY 10022 |
X | |||
| /s/ Carlye S. Landin as Attorney-in-Fact for Easton Capital Partners, LP pursuant to Power of Attorney previously filed. | 02/27/2009 | |
| **Signature of Reporting Person | Date |
| * | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | Immediately prior to the consummation of the merger between the issuer and Replidyne, Inc., each share of Series A convertible preferred stock was converted into approximately 1.005 shares of the issuer's common stock. |
| (2) | Disposed of pursuant to a merger agreement among the issuer, Responder Merger Sub, Inc. and Replidyne, Inc. (now known as "Cardiovascular Systems, Inc."), pursuant to which each share of the issuer's common stock was converted into 0.647 shares of common stock of Replidyne, Inc. |
| (3) | Immediately prior to the consummation of the merger between the issuer and Replidyne, Inc., each Series A convertible preferred stock warrant was converted into a warrant to purchase the issuer's common stock; each Series A convertible preferred share covered by the warrants was converted into approximately 1.005 shares of the issuer's common stock and the exercise price of each warrant was adjusted by multiplying the number of Series A shares covered by the warrant by the warrant exercise price, and dividing by the total number of the issuer's common shares subject to the converted Series A warrant. |
| (4) | Each share of Series A convertible preferred stock was convertible at any time, at the holder's election, into approximately 1.005 shares of common stock and had no expiration date. |
| (5) | Disposed of pursuant to a merger agreement among the issuer, Responder Merger Sub, Inc. and Replidyne, Inc. (now known as "Cardiovascular Systems, Inc."), pursuant to which each of the issuer's common stock warrants was assumed by Replidyne, Inc. and became exercisable to purchase shares of Replidyne, Inc. common stock; each share covered by the issuer's common stock warrants was converted into 0.647 shares of common stock of Replidyne, Inc., and the exercise price of each warrant was adjusted by dividing the pre-merger exercise price by 0.647 and rounding up to the nearest cent. |